News about Prescription Medicines

Loading...

Thursday, June 11, 2015

Personal Importation Medicine Advocate says Trans-Pacific Treaty disclosure calls for House to reject Fast Track, Congress to Launch Investigation of Pharma Tactics

The publisher of RxforAmericanHealth, a website dedicated to lowering prescription medicine prices for Americans by the use of personal importation of safe, affordable brand-name medicines says that the recently leaked disclosures of the tactics and goals of Pharma in the secret meetings of the Trans-Pacific Partnership calls for a Congressional investigation into the “totality of Pharma relationships to influence U.S. health care policy to its advantage free of public input”.
In his statement, Daniel Hines, who also publishes TodaysSeniorsNetwork and is preparing the launch of An American Rxbill of Rights site, noted:
“The leak from the Trans-Pacific Agreement is irrefutable evidence that Pharma is engaged in a series of actions in the US and Internationally to manipulate, ensure and protect its predatory pricing practices in the US, which represents a ‘safe haven’ for it to impose the highest prescription medicines in the world upon Americans, and to impose them upon a global scale.
“That Pharma engages in behind-closed-doors arrangements with  this Administration and Congress to implement its strategies has been evidenced for years with exorbitant campaign contributions to elected officials, and its often-times ‘too cozy’ relationship with the Food and Drug Administration.
“Now we see that Pharma has no limits within its sites.  Not content with ‘pay to delay’,  questionable patent extensions for designer medicines, or the potential of abusive seizures and possible destruction of safe, valid personally imported prescription medicines that are vital and affordable lifelines for millions of Americans, Pharma has set out to disrupt the authority of US policy-makers even more to the extent of further endangering the health and well-being of untold numbers of Americans by dictating procedures that would weaken the effectiveness of Medicare programs on which so many Americans rely and trust.
“For that reason, and, in the sake of transparency, it is imperative that there be a public awareness that will be best created by a Congressional investigation into the totality of the relationships of Pharma with policy-makers in the US.
“The House of Representatives is nearing a vote on whether the interests of Americans will be served with a vote denying fast-track authority, or, by passage, allowing Pharma to resurrect its goals free of any opportunity for oversight.

“The vote will be carefully monitored, and I am confident that advocacy and public interest groups will spare no effort to ensure that Americans are aware of the outcome,  urging them to let their Representatives know where they stand, and that any support of lack of transparency and accountability to the American public will not be acceptable in 2016.”

Friday, May 29, 2015

Generic Drug Prices Dropping More Slowly According to AARP Report


Publisher's Note:  It is becoming increasingly apparent that generic drug manufacturers are following the lead of Pharma in charging what the traffic will bear.  That is why it is imperative that steps be taken by Congress to act to ensure that the FDA/Pharma collusion does not lead to the senseless seizure and destruction of safe, valid, brand-name prescription medicines.  Personal importation can offer Americans a competitive option to being the victims of the highest prescription prescription medicine prices in the world.



Some generic drugs had substantial price decreases; others had equally substantial price increases

WASHINGTON, DC—The new Rx Price Watch Report released today by AARP Public Policy Institute(PPI) shows a number of popular generic drugs had substantial price increases, with some prices going up as much as 1,000%. Overall, retail prices for generic prescription drugs widely used by older Americans fell an average of 4% in 2013. Although generic drug prices have been consistently declining over the past several years, the latest annual data available showed the smallest average annual decline since at least 2006, a sign that the era of falling prices for generic drugs could be coming to an end.
The new PPI report looked at the 2013 retail prices for 280 of the generic drugs most widely used by older Americans. The report shows that the majority (73%) of widely used generic drug products included in the study experienced price decreases, some of them substantial.  
“Declining generic drug prices have helped many Americans’ pocketbooks, particularly older adults on fixed incomes,” said Debra Whitman, PhD, AARP Executive Vice President for Policy. “Unfortunately, recent trends indicate that we may not be able to rely on these savings forever.”
Nearly two-thirds of older Americans use three or more prescription drugs a year, according to the report. If these people used three generic drugs on a chronic basis in 2013, they would have paid an average annual retail price of therapy of $849. In contrast, the average annual retail price of therapy for three brand name medications used on a chronic basis was more than 10 times higher ($8,880) over the same period.
Highlights of the 2013 Rx Price Watch Report
Based on the market basket of 280 generic drugs widely used by older Americans:
  • On average, retail prices of widely used generic drugs fell by 4% in 2013
  • 73% had retail price decreases
  • 27% had retail price increases
  • 11 drugs had retail price increases of greater than 30%
  • $283: Average annual cost for a generic drug used for a chronic condition
According to the AARP PPI Report, more than 75% of all retail prescriptions filled in the US are for generic drugs. Lower cost generic drugs help consumers and third-party payers—such as private health insurers and state and federal programs—manage the high cost of prescription drugs.
“Many brand name drugs have generic equivalents that are every bit as safe and effective but typically cost much less than their brand name counterparts,” said Leigh Purvis, MPA, PPI Director of Health Services Research and co-author of the new report. “As more and more new brand name drugs and biologic drugs enter the market with extremely high prices, it will be more important than ever that people have generic medications to help with their budgets.” 
AARP’s Public Policy Institute, in collaboration with the PRIME Institute at the University of Minnesota, developed a market basket of 280 generic prescription drug products widely used by older Americans. Using data from the Truven Health MarketScan® Research Databases, the report analyzed retail price changes between 2006 and 2013 for the drug products in the market basket. The medications include products used to treat common and often chronic health conditions, including high cholesterol, depression, diabetes, and hypertension.
#  #  #
Additional Resources

Wednesday, May 13, 2015

Sanders Urges VA to Use Emergency Powers to Save Lives of Veterans with Liver Disease



Publisher's note:  Senator Sanders uses the power to rescind patent protection as punishment for companies profiteering from excessive drug prices.  This has been recommended before by many who believe the threat of rescinding the unique and long-lived patent protection provided for Pharma is one method of bringing prices into line. Simply put,a drug that is unaffordable is unavailable, and since the US Taxpayer fist helps subsidize the development of new drugs, American citizens should have a stakeholder position.  We applaud Senator Sanders

WASHINGTON, May 12 – Sen. Bernie Sanders (I-Vt.) today asked the Department of Veterans Affairs to invoke emergency powers to make expensive hepatitis C drugs available at affordable prices to treat tens of thousands of veterans now being denied the most effective care.

The VA recently stopped enrolling veterans in successful new treatments for the often deadly liver disease because the department already had spent the more than $400 million it had budgeted for the costly drugs.

The high-profit hepatitis C drugs are among the most expensive medications on the market. Gilead Sciences makes two of the new blockbuster medications and charges $1,000 per pill.

That adds up to $84,000 over the course of caring for a single patient. Even with a discount, the large VA health care system still drained its budget for treating hepatitis C.

Sanders’ proposal would make it possible for the VA, which already has treated about 20,000 veterans for hepatitis C, to afford to care for the estimated 200,000 additional veterans enrolled in VA health care who are believed to have the disease.

In a letter to VA Secretary Robert McDonald, Sanders urged him to authorize the manufacture or importation of the drug for VA patients at a fraction of what is being charged by the companies which hold patents on the medications.

“Our nation’s veterans cannot and should not be denied treatment while drug companies rake in billions of dollars in profits,” Sanders said in the letter. He noted that the new medications could cure many more patients with far fewer side effects.

 “We must not allow corporate greed to stand in the way of this potential.”The legal provision Sanders cited has been used in the past to stop profiteering by defense contractors in wartime. 

The threat of using the same law by the administration of President George W. Bush persuaded Bayer, which held a patent on Cipro, to dramatically cut the price of the antibiotic after anthrax-laced letters were mailed to Capitol Hill and news media offices in 2001.

“One solution to this would be for Gilead Sciences to simply provide the drug to VA at no cost,” Sanders said. “However, the company has not stepped up to do this for our country’s veterans.

As chairman of the Senate Committee on Veterans’ Affairs, Sanders last year held a hearing on the high price of hepatitis C medications. 

Now serving as ranking member of the Senate Budget Committee, Sanders said using the government’s existing authority to have the hepatitis C drugs manufactured or imported at lower cost would save taxpayers billions of dollars now going to the pharmaceutical companies

Monday, May 11, 2015

Time for A Congressional Caucus to support Congress moves on Personal Importation

The publisher of RxforAmericanHealth says that it is time for Congress to form a Congressional Caucus to support recently introduced legislative proposals on behalf of the personal importation of safe, affordable prescription medicines, and to act as a watchdog to prevent the potential of abuse by the Food and Drug Administration of Section 708 of the Food and Drug Administration Safety Innovation Act (FDASIA) with the unwarranted destruction of valid, safe medicines personally imported by Americans.

Daniel Hines, publisher of RxforAmericanHealth and TodaysSeniorsNetwork, notes that there is a reservoir of support in the US Congress for the proven safety and efficacy of personal importation. He cites the introduction of S.122, The Safe and Affordable Medicines from Canada Act by Senators John McCain (R-AZ) and Amy Klobuchar (D-MN) with co-sponsors Senators Charles Grassley (R-IA) and Senator Sheldon Whitehouse (D-RI), and HR.2228, the companion bill of the same name in the House of Representatives, introduced by Representative Chellie Pingree (R-ME1) and co-sponsored by Representative Dana Rohrabacher (R-CA48).

“The introduction of the two bills is encouraging since it is a logical extension of a ruling by a Federal Circuit Court in Maine.” Hines says.

“While overturning a state-passed law that extended a long-standing practice of Maine citizens of personally importing prescription medicines to include Canada, Australia, New Zealand and The United Kingdom, the Court did not suggest that personal importation was unsafe or even illegal, but was the responsibility of the US Congress,” Hines explains.

The Court ruling noted that Congress has in fact acted many times with votes of support for personal importation, that were not fully enacted because of amendments restricting importation by imposition of a ‘certification’ clause.

“Nonetheless, it is obvious that Congress is indeed empowered to enact such legislation,” Hines says.

In a blog at RxforAmericanHealth, Hines presents a list of issues that support the need for a Congressional Caucus:
  • Rising prescription medicine costs that have created awareness of the harmful impact of the predatory pricing practices of Pharma upon Americans’ finances, health and well-being, and that prescription medicine costs are a major driver of health care costs;
  • Taking the responsibility and opportunity created by a Maine Circuit Court ruling earlier this year that ruled that is Congress’ responsibility and is within its authority to determine how personal importation should be implemented, not unelected rules promulgators; 
  • The need and opportunity to act upon the ‘reservoir of good will’ towards personal importation by numerous members of Congress to the benefit of Americans;
  • Pharma’s questionable pricing strategies, including but not limited to, Pay and Delay to protect generics from entering the market; Purchasing products from other companies and then raising the prices; Claiming extraordinary R&D investments when in reality a high percentage of the ‘new’ medicines are created through grants to University laboratories from the National Institute of Health, a governmental and tax-payer-funded entity; 
  • Acknowledging that medicine that is ‘unaffordable’ is equally indeed ‘unavailable’ causing 55 million Americans failure to adhere to their prescribed regimen of taking their medicines simply because they cannot afford them;
  • The potential for FDA abuse of Section 708 of the Food Drug Administration Safety Innovation Act (FDASIA) by declaring that a drug may be consider ‘illegal’ because of a slight difference in labeling even though it is a perfectly safe, valid brand-name medicine that is the same as the medicine sold in the US at prices at prices as much as 60 percent higher;
  • The spectacle of the FDA, ostensibly designed to protect the health and well-being of Americans seizing Americans’ medicines and the possible destruction of those medicines, creating untold bad health consequences of Americans being denied access to safe, affordable medicines
“A Congressional Caucus for Personal Importation can ensure that it is Congress, not regulators, that determine what American policy regarding prescription medicines should be,” Hines concludes. “This should be a leading issue for the 2016 elections for all candidates.”

Tuesday, May 5, 2015

Time for A Congressional Caucus to support Congress moves on Personal Importation

Publisher’s Note:  In this post, we applaud the introduction of bills in Congress in support of personal importation, while questioning the breadth of Congressional knowledge of the extent of the harmful consequences of protecting the safe haven provided in the US for the highest prescription prices in the Industrial World.  We continue our call for an Rx Bill of Rights for Americans, and urge that Congress form a Congressional caucus for Personal Importation as a first step to ensure that the vast numbers of Americans adversely affected by Pharma pricing have a voice in shaping health policies and continue to utilize the health and fiscal benefits made possible by personal importation.

Some simple questions for Congress:

  • Is it prepared for the spectacle of an agency ostensibly designed to protect the health and well-being of Americans—the FDA—seizing Americans’ medicines, holding them for an individual to ‘appeal’ the seizure (a complete sacrilege of the rights of Americans to due process by making their personal property subject to what are invalid seizures of their personal property, i.e., safe, valid medicines) and then, the eventual possible destruction of those medicines?                                                                       

Now, Congress has once again introduced two bills—S.122, co-sponsored by Senators John McCain (R-AZ) and Amy Klobuchar (D-MN), and HR 2228, sponsored by Representative Chellie Pingree (D-ME 1)  Dana Rohranbacher (R-CA 48)

The bills are designed to allow the personal importation of safe, affordable medicines from Canadian pharmacies.

The chances of passage are slim to none according to https://www.govtrack.us/congress/bills/114/hr2228 which gives each bill a less than four percent chance of passage, leading us to our list above of questions for Congress.

We are recommending something more--that the sponsors of the bills send ‘Dear Colleague’ letters and engage in colloquies with their fellow members. Most importantly, we believe it is time for the formation of a Congressional Caucus comprised of Senate and House members to act in support of personal importation legislation, and to also allow Americans a place at the table thereby generating additional awareness of what the consequences will be of Pharma unchecked.  This will, thereby provide the basis for an Rx Bill of Rights for Americans, which could also act as a strategy map for lowering the outrageous pricing practices of Pharma.

Wednesday, April 22, 2015

Why did the FDA make a statement about Health Canada that gives False Impression of Safety, Efficacy

The publisher of a leading informational website on the high cost of prescription medicines in the U.S. says Congressional supporters of personal importation of safe, affordable prescription medicines should demand that the U.S. Food and Drug Administration explain why it says that it is ‘unable’ to ‘ensure’ the safety and efficacy of prescription medicines approved by Health Canada for sale in Canada, if those medicines are purchased by U.S. citizens.

Daniel Hines, publisher of RxforAmericanHealth and TodaysSeniorsNetwork says that on its website, the FDA notes:  “... if a drug is approved by Health Canada (FDA’s counterpart in Canada) but has not been approved by FDA, it is an unapproved drug in the United States and, therefore, illegal to import. FDA cannot ensure the safety and effectiveness of drugs that it has not approved.”

“This statement is a reflection of the flawed reasoning and overreach of the FDA,” says. Hines.  He points out that Health Canada is internationally recognized for its proven record of professionalism and safety in its oversight of the Canadian health system.

“As a matter of fact, Health Canada and the FDA have indeed independently reviewed and approved many of the same brands of medicines. The only distinction is that the labeling of the Canadian medicine is different from that of the same medicine sold in the U.S,” Hines explains.

Hines points out that by suggesting that Health Canada does not have the expertise to determine the safety and efficacy of a medicine, the FDA has moved from being a regulatory agency to taking an advocacy stance that flies in the face of the facts, and undertaken a stance that is directly contrary to legislation introduced in the U.S.Congress.

 He points to S. 122, a bi-partisan bill introduced by Senators Amy Klobuchar (D-MN) and John McCain (R-AZ) calling specifically for facilitating personal importation of medicines from Canada that are approved by Canadian Provincial authorities, which are subject to the oversight of Health Canada.

“This is a recognition of the safety of medicines approved by Health Canada, and by extension, the regulatory agencies of other Tier One countries whose standards of safety and efficacy meet or exceed those of the U.S.,” Hines says.

“One can only hope that Senators Klobuchar and McCain demand that the FDA retract this disingenuous statement about Health Canada, an agency of the highest repute, and ensure that the FDA not make such statements about legislation awaiting consideration of the United States Congress in the future ,” he says.

He concludes that the stance of the FDA should also be questioned as to its relationship with Pharma since the FDA stance reflects the claims of Pharma.

He also urges that Congress be alert to what supporters of personal importation fear will be a misguided application of Section 708 of the Food and Drug Administration Safety and Innovation Act that runs contrary to Congressional intent.

“The soon-to-be-announced rules for administration of Section 708 which authorizes the seizure and destruction of imported prescription medicines deemed to be counterfeit, unsafe, or ‘misbranded’, takes on special importance since if medicines approved by such an internationally respected authority as Health Canada are deemed to be ‘illegal’ or ‘unsafe’, the FDA will, almost certainly rule the same is true of other countries.

“This will lead to the spectacle of the FDA-- an agency ostensibly designed to protect and promote the health and well-being of Americans --doing just the opposite by destroying valid personally imported vital medications which, at prices of as much as 60 percent more in the U.S., are unavailable because they are unaffordable.

“The only beneficiary of such action will be Pharma, as the FDA endangers one of the few avenues of relief for Americans from the industry’s predatory pricing practices.”


Monday, April 20, 2015

‘Curiouser and Curiouser!’ The Alice in Wonderland World of the FDA



Alice in Wonderland, recognized as a‘Children’s Classic, also is a reflection of our own Wonderland populated by strange creatures whom, as one sees and hears more of them, we discover that, as Alice said, things get ‘Curiouser and Curiouser.’

 It’s called The Beltway, a reference to the seat of our Federal government (although several agencies have headquarters outside the ‘physical boundaries’ of The Beltway, it is the ‘Source’ or Mother head from which all our laws and regulations flow).

It is comprised of both elected and unelected persons who make decisions that affect our everyday lives, our health and well-being, and our prosperity...and not always for the best. 

That’s because, unfortunately, the things that they do too often reflect special interests, are based on self-contradictory stances, and exhibit complete disregard for facts that disrupt their Wonderland.

The most notable example of this denial of facts is evidenced by the Food and Drug Administration (FDA) decisions affecting the right—and the need—of Americans to make personal, responsible decisions to determine that safe and affordable brand-name medicines are indeed available from licensed, registered pharmacies in Tier One Countries whose standards of safety and efficacy meet or exceed those of the FDA, and are therefore safe sources for them to use to purchase their medications.

The FDA reflects Alice’s thoughts even before she descends into Wonderland.  Consider this telling quote she makes:  “If I had a world of my own, everything would be nonsense. Nothing would be what it is, because everything would be what it isn't. And contrary wise, what is, it wouldn't be. And what it wouldn't be, it would. You see?”

Yes, Alice and FDA we see.  Both of you believe you have a world of your own and it is subject to the bending of your will, even though the FDA was ostensibly designed to protect the health and well-being of American citizens, ensuring among other things that the prescription medicines made available to Americans are indeed safe and effective.

That is why the ‘Long Title’ of The Prescription and Drug Marketing Act of 1987 is: An Act to amend the Federal Food, Drug, and Cosmetic Act to ban the reimportation of drugs produced in the United States, to place restrictions on the distribution of drug samples, to ban certain resales of drugs by hospitals and other health care facilities, and for other purposes.

Although, the ‘reimportation’ mention is specific to restrictions upon reimporting medicines produced in the US, marketed outside the Country and then brought back into the US, i.e., ‘reimportation’, the FDA, in collusion with the special interests of Pharma  shapes its and our world with that ‘reimportation’ of prescription medicines somehow doesn’t mean what it means.

To come to such a conclusion, the FDA and Pharma say that the law doesn’t mean what it means.


Significantly, all the Lipitor produced by Pfizer for sale in the US is manufactured in Ireland for sale in the US and elsewhere.  That means it is imported into this country, whether by Pfizer or by individuals. 

Pfizer, as the manufacturer of Lipitor has the right, of course, to sell the medicines it produces, but in the absence of any restriction upon the right of individuals to personally import their medicines, then it is self-evident that Americans do indeed have the right to personally import their Lipitor and other prescription medicines.

In yet another example of Wonderland-speak, the FDA refers to seized personally imported Lipitor prescriptions as a ‘new drug’ or a drug not approved by the FDA, although it clearly is a valid medicine ordered by an individual with a doctor’s prescription.  So, says the FDA,  it is not what it is.

A further reading of The Prescription and Drug Marketing Act of 1987 makes it abundantly clear that the law’s intent is to ban ‘certain’ resales of reimported medicines “by hospitals and other health care facilities...” and there is no intent to restrict Americans from purchasing their medicines via personal importation, except for the FDA creating its own world where nothing is what it seems.

But perhaps the best example of this bizarre world is on the FDA’s own web page as it answers the question: Is it legal to import prescription medicines?

The FDA response:  “In most circumstances, it is illegal for individuals to import drugs into the United States for personal use. This is because drugs from other countries that are available for purchase by individuals often have not been approved by FDA for use and sale in the United States. For example, if a drug is approved by Health Canada (FDA’s counterpart in Canada) but has not been approved by FDA, it is an unapproved drug in the United States and, therefore, illegal to import. FDA cannot ensure the safety and effectiveness of drugs that it has not approved.”

Let’s take this point-by-point:

FDA Statement: In most circumstances, it is illegal for individuals to import drugs into the United States for personal use. This is because drugs from other countries that are available for purchase by individuals often have not been approved by FDA for use and sale in the United States.

Common Sense Response:  The FDA says drugs sold in other countries to their citizens ‘often’ have not been approved by the FDA.  The use of the term ‘often’ indicates that there are some drugs that the FDA has approved.  The FDA should let us know which of those medicines have been approved...or should the ‘often’ term be ‘never’?  (The answer is ‘never’.)

FDA Statement: “For example, if a drug is approved by Health Canada (FDA’s counterpart in Canada) but has not been approved by FDA, it is an unapproved drug in the United States and, therefore, illegal to import. FDA cannot ensure the safety and effectiveness of drugs that it has not approved.”

Common Sense Response:  This is the winner of the Wonderland double-talk award.  Senator Bernie Sanders (I-VT) has asked opponents of personal importation: “Where are all the Dead Canadians”.  It is ludicrous of the FDA to say that a medicine approved by Health Canada is inferior to that of the FDA.  Also, the FDA talks about  challenges in ‘ensuring’ the safety of the drug, even though it is the same medicine as sold in the US. 

This statement is also a reflection of the abuse and overreach of the FDA.  Congress has repeatedly supported personal importation in favorable votes only to be stymied by unprecedented ‘certification’ requirements by the Secretary of Health and Human Services.  Now, S. 122, a bi-partisan bill introduced by Senators Amy Klobuchar (D-MN) and John McCain (R-AZ) calls specifically for facilitating personal importation of medicines from Canada that are approved by Health Canada.

By suggesting that Health Canada dos not have the expertise to determine the safety and efficacy of a medicine, the FDA has moved from being a regulatory agency to an advocacy stance that flies in the face of the facts, and undertaken a legislative initiative that is outside its legal boundaries as a department of the executive branch.

One can only hope that Senators Klobuchar and McCain will demand that the FDA remove this incorrect statement about Health Canada, an agency of the highest repute.


At least for Canadians?  Really, is there a genetic distinction between Americans and Canadians that makes a prescription safe for Canadians, but somehow unsafe for Americans?  Not hardly. But then, in this world of outlandish claims, everything is nonsense. Nothing is what it is, because everything would be what it isn't. And contrary wise, what is, it wouldn't be. And what it wouldn't be, it would.

“You see?”

It is time for Congress to step up and end this Alice in Wonderland scenario and to direct the FDA to cease attempts to increase its intended limited authority, and to work on behalf of the millions of Americans who are being denied their access to safe, affordable medicines because of illogical and contradictory actions that usurp legislative oversight and direction of the agency. Otherwise, things will get ‘Curiouser and Curiouser’!